Recently, targeting the JAK2‐STAT3 signaling pathway has become a hot spot for cancer therapy, and a variety of JAK2‐STAT3 inhibitors have been identified that induce antitumor activity both in vitro and in vivo. Here, JAK2 is linked to cancer.